NEW YORK (GenomeWeb) – Signal Genetics today priced its public offering of 3,214,285 shares of common stock at $2.80 per share. 

Gross proceeds from the offering are anticipated to be about $9 million and will go toward the clinical development of new products and services, expansion of the company's commercialization efforts, working capital, and general corporate purposes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.